| Description | JGB1741 (ILS-JGB-1741) is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer. |
| In vitro | JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression[1]. |
| Synonyms | ILS-JGB-1741 |
| molecular weight | 440.56 |
| Molecular formula | C27H24N2O2S |
| CAS | 1256375-38-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 4.41 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Arunasree M Kalle, et al. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2010 Oct 8;401(1):13-9. |